{"id":927289,"date":"2026-01-14T08:59:15","date_gmt":"2026-01-14T13:59:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/"},"modified":"2026-01-14T08:59:15","modified_gmt":"2026-01-14T13:59:15","slug":"clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/","title":{"rendered":"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\/IIa Clinical Trial for CMND-100"},"content":{"rendered":"
\n

Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I\/IIa clinical trial evaluating CMND-100, the Company\u2019s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).<\/p>\n

The second cohort, consisting of six patients recruited across premier clinical sites, including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, has now fully completed the treatment per protocol. This milestone builds on the positive results from the first cohort, which demonstrated a favorable safety profile and preliminary efficacy signals, including reduced cravings and withdrawal symptoms.<\/p>\n

\u201cWe are pleased to announce the successful completion of treatment in the second cohort, within a month after receiving DSMB approval to continue enrollment, marking continued steady progress in our multinational Phase I\/IIa trial,\u201d said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. \u201cThis achievement reflects the dedication of our clinical sites and the strong interest in CMND-100 as a potential innovative therapy for AUD, a condition with significant unmet medical needs. We look forward to upcoming data readouts and advancing toward subsequent cohorts.\u201d<\/p>\n

The Phase I\/IIa trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Topline results from the second cohort are anticipated in the coming months.<\/p>\n

\n About\u00a0Clearmind\u00a0Medicine Inc.<\/b>\n <\/p>\n

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.<\/p>\n

The Company\u2019s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.<\/p>\n

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol \u201cCWY0.\u201d<\/p>\n

For further information, visit:\u00a0https:\/\/www.clearmindmedicine.com<\/a>\u00a0or contact:<\/p>\n

Investor Relations
invest@clearmindmedicine.com<\/a><\/p>\n

Telephone: (604) 260-1566
US:\u00a0CMND@crescendo-ir.com<\/a><\/p>\n

General Inquiries
Info@Clearmindmedicine.com<\/a>
www.Clearmindmedicine.com<\/a><\/p>\n

\n Forward-Looking Statements:<\/b>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates\u201d and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses progress in our multinational Phase I\/IIa trial, interest in CMND-100 as a potential innovative therapy for AUD and advancing toward subsequent cohorts. Forward-looking statements are not historical facts, and are based upon management\u2019s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith.\u00a0However, there can be no assurance that management\u2019s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is\u00a0made to the Company\u2019s reports filed from time to time with the Securities and Exchange Commission (\u201cSEC\u201d), including, but not limited to, the risks detailed in the Company\u2019s annual report on Form 20-F for the fiscal year ended October 31,\u00a02024\u00a0and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I\/IIa clinical trial evaluating CMND-100, the Company\u2019s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). The second cohort, consisting of six patients recruited across premier clinical sites, including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, has now fully completed the treatment per protocol. This milestone builds on the positive results from the … <\/p>\n

Continue reading “Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\/IIa Clinical Trial for CMND-100”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-927289","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nClearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\/IIa Clinical Trial for CMND-100 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\/IIa Clinical Trial for CMND-100 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I\/IIa clinical trial evaluating CMND-100, the Company\u2019s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). The second cohort, consisting of six patients recruited across premier clinical sites, including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, has now fully completed the treatment per protocol. This milestone builds on the positive results from the … Continue reading "Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\/IIa Clinical Trial for CMND-100"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-14T13:59:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\\\/IIa Clinical Trial for CMND-100\",\"datePublished\":\"2026-01-14T13:59:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/\"},\"wordCount\":788,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/\",\"name\":\"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\\\/IIa Clinical Trial for CMND-100 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA==\",\"datePublished\":\"2026-01-14T13:59:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\\\/IIa Clinical Trial for CMND-100\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\/IIa Clinical Trial for CMND-100 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/","og_locale":"en_US","og_type":"article","og_title":"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\/IIa Clinical Trial for CMND-100 - Market Newsdesk","og_description":"Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I\/IIa clinical trial evaluating CMND-100, the Company\u2019s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). The second cohort, consisting of six patients recruited across premier clinical sites, including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, has now fully completed the treatment per protocol. This milestone builds on the positive results from the … Continue reading \"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\/IIa Clinical Trial for CMND-100\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-14T13:59:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\/IIa Clinical Trial for CMND-100","datePublished":"2026-01-14T13:59:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/"},"wordCount":788,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/","name":"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\/IIa Clinical Trial for CMND-100 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA==","datePublished":"2026-01-14T13:59:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-successful-completion-of-treatment-in-all-patients-of-the-second-cohort-in-ongoing-phase-i-iia-clinical-trial-for-cmnd-100\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I\/IIa Clinical Trial for CMND-100"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/927289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=927289"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/927289\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=927289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=927289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=927289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}